Gregory A Fonzo1, Madeleine S Goodkind1, Desmond J Oathes1, Yevgeniya V Zaiko1, Meredith Harvey1, Kathy K Peng1, M Elizabeth Weiss1, Allison L Thompson1, Sanno E Zack1, Steven E Lindley1, Bruce A Arnow1, Booil Jo1, James J Gross1, Barbara O Rothbaum1, Amit Etkin1. 1. From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif.; the Stanford Neurosciences Institute, Stanford University, Stanford; the Sierra Pacific Mental Illness, Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Healthcare System, Palo Alto, Calif.; the New Mexico Veterans Affairs Healthcare System, Albuquerque; the Center for Neuromodulation in Depression and Stress, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia; and the Trauma and Anxiety Recovery Program, Department of Psychiatry, Emory University School of Medicine, Atlanta.
Abstract
OBJECTIVE:Exposure therapy is an effective treatment for posttraumatic stress disorder (PTSD), but many patients do not respond. Brain functions governing treatment outcome are not well characterized. The authors examined brain systems relevant to emotional reactivity and regulation, constructs that are thought to be central to PTSD and exposure therapy effects, to identify the functional traits of individuals most likely to benefit from treatment. METHOD: Individuals with PTSD underwent functional MRI (fMRI) while completing three tasks assessing emotional reactivity and regulation. Participants were then randomly assigned to immediate prolonged exposure treatment (N=36) or a waiting list condition (N=30). A random subset of the prolonged exposure group (N=17) underwent single-pulse transcranial magnetic stimulation (TMS) concurrent with fMRI to examine whether predictive activation patterns reflect causal influence within circuits. Linear mixed-effects modeling in line with the intent-to-treat principle was used to examine how baseline brain function moderated the effect of treatment on PTSD symptoms. RESULTS: At baseline, individuals with larger treatment-related symptom reductions (compared with the waiting list condition) demonstrated 1) greater dorsal prefrontal activation and 2) less left amygdala activation, both during emotion reactivity; 3) better inhibition of the left amygdala induced by single TMS pulses to the right dorsolateral prefrontal cortex; and 4) greater ventromedial prefrontal/ventral striatal activation during emotional conflict regulation. Reappraisal-related activation was not a significant moderator of the treatment effect. CONCLUSIONS: Capacity to benefit from prolonged exposure in PTSD is gated by the degree to which prefrontal resources are spontaneously engaged when superficially processing threat and adaptively mitigating emotional interference, but not when deliberately reducing negative emotionality.
RCT Entities:
OBJECTIVE: Exposure therapy is an effective treatment for posttraumatic stress disorder (PTSD), but many patients do not respond. Brain functions governing treatment outcome are not well characterized. The authors examined brain systems relevant to emotional reactivity and regulation, constructs that are thought to be central to PTSD and exposure therapy effects, to identify the functional traits of individuals most likely to benefit from treatment. METHOD: Individuals with PTSD underwent functional MRI (fMRI) while completing three tasks assessing emotional reactivity and regulation. Participants were then randomly assigned to immediate prolonged exposure treatment (N=36) or a waiting list condition (N=30). A random subset of the prolonged exposure group (N=17) underwent single-pulse transcranial magnetic stimulation (TMS) concurrent with fMRI to examine whether predictive activation patterns reflect causal influence within circuits. Linear mixed-effects modeling in line with the intent-to-treat principle was used to examine how baseline brain function moderated the effect of treatment on PTSD symptoms. RESULTS: At baseline, individuals with larger treatment-related symptom reductions (compared with the waiting list condition) demonstrated 1) greater dorsal prefrontal activation and 2) less left amygdala activation, both during emotion reactivity; 3) better inhibition of the left amygdala induced by single TMS pulses to the right dorsolateral prefrontal cortex; and 4) greater ventromedial prefrontal/ventral striatal activation during emotional conflict regulation. Reappraisal-related activation was not a significant moderator of the treatment effect. CONCLUSIONS: Capacity to benefit from prolonged exposure in PTSD is gated by the degree to which prefrontal resources are spontaneously engaged when superficially processing threat and adaptively mitigating emotional interference, but not when deliberately reducing negative emotionality.
Authors: R J L Lindauer; J Booij; J B A Habraken; E P M van Meijel; H B M Uylings; M Olff; I V E Carlier; G J den Heeten; B L F van Eck-Smit; B P R Gersons Journal: Psychol Med Date: 2007-09-06 Impact factor: 7.723
Authors: Steven M Nelson; Nico U F Dosenbach; Alexander L Cohen; Mark E Wheeler; Bradley L Schlaggar; Steven E Petersen Journal: Brain Struct Funct Date: 2010-05-29 Impact factor: 3.270
Authors: Erin Falconer; Adrian Allen; Kim L Felmingham; Leanne M Williams; Richard A Bryant Journal: J Clin Psychiatry Date: 2013-09 Impact factor: 4.384
Authors: Gregory A Fonzo; Madeleine S Goodkind; Desmond J Oathes; Yevgeniya V Zaiko; Meredith Harvey; Kathy K Peng; M Elizabeth Weiss; Allison L Thompson; Sanno E Zack; Colleen E Mills-Finnerty; Benjamin M Rosenberg; Raleigh Edelstein; Rachael N Wright; Carena A Kole; Steven E Lindley; Bruce A Arnow; Booil Jo; James J Gross; Barbara O Rothbaum; Amit Etkin Journal: Am J Psychiatry Date: 2017-07-18 Impact factor: 18.112
Authors: Jerome A Yesavage; J Kaci Fairchild; Zhibao Mi; Kousick Biswas; Anne Davis-Karim; Ciaran S Phibbs; Steven D Forman; Michael Thase; Leanne M Williams; Amit Etkin; Ruth O'Hara; Gerald Georgette; Tamara Beale; Grant D Huang; Art Noda; Mark S George Journal: JAMA Psychiatry Date: 2018-09-01 Impact factor: 21.596
Authors: Katharina Kircanski; Lauren K White; Wan-Ling Tseng; Jillian Lee Wiggins; Heather R Frank; Stefanie Sequeira; Susan Zhang; Rany Abend; Kenneth E Towbin; Argyris Stringaris; Daniel S Pine; Ellen Leibenluft; Melissa A Brotman Journal: JAMA Psychiatry Date: 2018-06-01 Impact factor: 21.596
Authors: Amit Etkin; Adi Maron-Katz; Wei Wu; Gregory A Fonzo; Julia Huemer; Petra E Vértes; Brian Patenaude; Jonas Richiardi; Madeleine S Goodkind; Corey J Keller; Jaime Ramos-Cejudo; Yevgeniya V Zaiko; Kathy K Peng; Emmanuel Shpigel; Parker Longwell; Russ T Toll; Allison Thompson; Sanno Zack; Bryan Gonzalez; Raleigh Edelstein; Jingyun Chen; Irene Akingbade; Elizabeth Weiss; Roland Hart; Silas Mann; Kathleen Durkin; Steven H Baete; Fernando E Boada; Afia Genfi; Jillian Autea; Jennifer Newman; Desmond J Oathes; Steven E Lindley; Duna Abu-Amara; Bruce A Arnow; Nicolas Crossley; Joachim Hallmayer; Silvia Fossati; Barbara O Rothbaum; Charles R Marmar; Edward T Bullmore; Ruth O'Hara Journal: Sci Transl Med Date: 2019-04-03 Impact factor: 17.956
Authors: Xi Zhu; Benjamin Suarez-Jimenez; Amit Lazarov; Liat Helpman; Santiago Papini; Ari Lowell; Ariel Durosky; Martin A Lindquist; John C Markowitz; Franklin Schneier; Tor D Wager; Yuval Neria Journal: Depress Anxiety Date: 2018-09-10 Impact factor: 6.505
Authors: Kelly R Bijanki; Sanne J H van Rooij; Timothy D Ely; Jennifer S Stevens; Cory S Inman; Rebecca E Fasano; Sierra E Carter; Sterling J Winters; Justin R Baman; Daniel L Drane; Tanja Jovanovic; Jon T Willie Journal: Neurosurgery Date: 2020-09-15 Impact factor: 4.654